Releases

17/10/2017
Australian Scientists awarded $2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease
Applications Open for CSL Centenary Fellowship Program Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance understanding of what really causes our arteries to clog.
 
More.

05/10/2017
New Debt Facilities
ASX Announcement

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 4 October 2017 it closed a new USD700 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2017.

More.

03/08/2017
CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator
CSL Limited today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.
 
More.

10/07/2017
CSL Response to Patent Infringement Complaint
ASX Announcement

CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission.

More.

All News Releases >


Media Resources

CSL Behring Company Information
CSL Company Information >
CSL Behring Media Contacts
CSL Media
Contacts >
CSL Behring Social Media
CSL Social
Media >
CSL Behring MultiMedia Library
CSL Media
Library >

© 2017 CSL Limited